<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675233</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000595166</org_study_id>
    <secondary_id>I 119207</secondary_id>
    <nct_id>NCT00675233</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx</brief_title>
  <official_title>Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Larynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is&#xD;
      exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may&#xD;
      be an effective treatment for laryngeal cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of laser light therapy&#xD;
      when given together with HPPH in treating patients with dysplasia, cancer in situ, or&#xD;
      invasive cancer of the larynx.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of laser light therapy using a fixed dose of&#xD;
           HPPH in patients with dysplasia, squamous cell carcinoma in situ, or T1 squamous cell&#xD;
           carcinoma of the larynx.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of laser light therapy.&#xD;
&#xD;
      Patients undergo photodynamic therapy comprising HPPH IV over 1 hour on day 1 and laser light&#xD;
      therapy to the tumor on day 2. Approximately 8 weeks later, patients with a partial response,&#xD;
      no response, or a geographical miss may receive a second course of treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 week, 1 month, 3 months, and&#xD;
      then periodically thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2008</start_date>
  <completion_date type="Actual">September 27, 2018</completion_date>
  <primary_completion_date type="Actual">June 28, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPPH</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment PDT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laser therapy</intervention_name>
    <description>Escalating light doses with 665 nm light</description>
    <arm_group_label>Treatment PDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy-confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Mild to severe dysplasia of the larynx&#xD;
&#xD;
                    -  Dysplastic lesions &gt; 3 mm in thickness&#xD;
&#xD;
               -  Squamous cell carcinoma in situ of the larynx&#xD;
&#xD;
               -  T1 squamous cell carcinoma of the larynx&#xD;
&#xD;
                    -  Tumor &gt; 3 mm in thickness&#xD;
&#xD;
                    -  No T2-T4 squamous cell carcinoma of the larynx&#xD;
&#xD;
          -  Newly diagnosed or recurrent disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Total bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  SGOT &gt; 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 3 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3-6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No porphyria&#xD;
&#xD;
          -  No hypersensitivity to porphyrin or porphyrin-like compounds&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Any prior therapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Arshad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2008</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage 0 laryngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

